




Potential for Broad Patients Benefits with Significant Upcoming Milestones

PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2	PHASE 3/ REGISTRATIONAL	WORLDWIDE OR GEOGRAPHIC PARTNER
SUTRO-LED PROGRAMS								
Luveltamab tazevibulin (Luvelta, STRO-002)	FR α Antibody-Drug Conjugate (ADC)	Ovarian Cancer						 天士力生物 TASLY BIOPHARMA (Greater China Rights)
		Ovarian Cancer (bevacizumab combo)						
		Endometrial Cancer						
		CBF/GLIS2 Pediatric AML						
		NSCLC						
STRO-004	Tissue Factor ADC	Solid Tumors						
Next Generation ADCs	ADC ² +	Solid Tumors						
PARTNER PROGRAMS								
VAX-24	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						 VAXCYTE <i>protect humankind</i>
VAX-31	31-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						
MK-1484	Selective IL-2 Agonist	Advanced or Metastatic Solid Tumors						 MERCK
STRO-003	ROR1 ADC	Solid Tumors & Hematological Cancers						 IPSEN
Undisclosed Programs	Immunostimulatory ADCs (iADCs)	Cancers						 astellas